Please ensure Javascript is enabled for purposes of website accessibility

Why Pacira Pharmaceuticals Shares Are Crashing 15% Today

By Todd Campbell - Jul 25, 2017 at 12:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Disappointing late-stage trial data is dashing investor optimism.

What happened

Pacira Pharmaceuticals (PCRX -1.66%) shares are down 15% at 12:00 p.m. EDT today following word that its pain medicine Exparel didn't perform as well as hoped in key phase 3 studies.

So what

Pacira Pharmaceuticals already markets the surgical-pain medicine Exparel, and its sales have been growing quickly as doctors embrace ways to control pain that may reduce a patient's need for rescue pain medications, like opioids.

A man holds his head in his hands while watching a stock price fall.


The potential to expand Exparel's use into new indications has helped Pacira Pharmaceuticals' share price rally over the past year, but enthusiasm was tempered today when management reported less-than-spectacular results in using it as a nerve block in total knee arthroplasty, or TKA.

Specifically, Exparel failed to statistically and significantly control pain in TKA patients. Management is blaming the failure on results from one center participating in the trial that didn't follow trial protocols; nevertheless, the data took the luster off positive trial results in patients undergoing shoulder surgery and rotator-cuff surgery.

In the shoulder-surgery trial, Exparel significantly reduced pain, and it reduced the use of opioids in recovering patients, both with p-values of <0.0001.

Now what

Exparel's sales increased 11%, to $276.4 million last year, and that performance translated into non-GAAP earnings per share of $0.62. This year, Exparel sales are expected to be between $290 million and $310 million, up 9% from 2016, at the low end.

Exparel's success suggests that, if results from these trials had been a slam-dunk success, it could've led to a speedy FDA green light that could drive sales and profit even higher. Management still thinks it has enough data to file for the label expansion, so it's possible an approval will still happen, but it's far less of a lock than it could've been.

Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pacira BioSciences, Inc. Stock Quote
Pacira BioSciences, Inc.
$56.26 (-1.66%) $0.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.